studiensammlung

Recommendations

Info

Downloaded by [77.21.82.66] at 09:13 04 March 2013 TABLE 3 Results from CIXI for Nicotine and Nicotine Related Impurities in Cartridges Expressed as mg=Cartridge Nicotine, Flavor Cotinine Myosmine Anatabine Anabasine Nicotine b-Nicotyrine None, regular ND
Downloaded by [77.21.82.66] at 09:13 04 March 2013 1454 M. L. Trehy et al. Nicotine Content of Refill Solutions Table 4 summarizes the results for nicotine content found on analyzing two manufacturers of electronic cigarette refill solutions. Johnson Creek consistently matched the label specification with the range 100.2% to 110.8% of label value. However, CIXI did not consistently match the label claim. The nicotine content followed the flavor labeling so that all ‘‘regular flavor’’ refill solutions did not contain nicotine even though they were labeled to contain variable concentrations of nicotine. Of greatest concern was the high nicotine content in refill solutions labeled to contain no nicotine. Nicotine and Nicotine Related Impurities in Puff Trapping Solutions Electronic cigarettes were found to deliver nicotine at a consistent rate for a given cartridge and electronic cigarette device as shown in Figure 6 when a constant puff pause interval of 1 min was used. However, cartridge contents vary significantly from one cartridge to another so that actual performance from one electronic cigarette cartridge combination to another is highly variable. This is especially true from one manufacturer to another. The variability within a single manufacturer and cartridge is similar to that observed when a popular cigarette was tested under the same conditions as shown in Table 5. Although, nicotine related impurities were not detected in the puffs above the LOQ for the electronic cigarettes, this is attributable to the lower nicotine delivery observed and not the absence of nicotine impurities in the TABLE 4 Nicotine Results for e-Cigarette Refills from Two Manufacturers CIXI Label mg Nicotine=mL (flavor) mg Nicotine=mL % of Label Johnson Creek Label mg Nicotine=mL (flavor) mg Nicotine=mL % of Label 0 (Regular Flavor) 0 – 24 (Original Smoke RPG) 25.6 106.5 24 (Regular Flavor) 0 0 24 (Tennessee Cured RPG) 25.4 106.0 16 (Regular Flavor) 0 0 24 (Tennessee Cured PG) 25.4 105.9 24 (Cialis) 13 54 18 (Tennessee Cured PG) 19.9 110.8 0 (Cialis) 12 – 0 (Tennessee Cured PG) 0.0 – 16 (Cialis) 13 81 24 (Simply Strawberry PG) 24.8 103.2 24 (Marlboro Flavor) 14 58 18 (Simply Strawberry PG) 18.0 100.2 0 (Rimonabant) 21 – 24 (Espresso PG) 24.9 103.6 24 (Rimonabant) 20 83 18 (Espresso PG) 18.8 104.4 16 (Rimonabant) 20 125 0 (Espresso PG) 0.0 – 24 (Original PG) 24.6 102.5 18 (Original PG) 18.9 105.2
Page 1 and 2: Nachschlagewerk zum Thema E-Zigaret
Page 7 and 8: Downloaded from tobaccocontrol.bmj.
Page 15 and 16: References Email alerting service D
Page 17 and 18: Eur Respir J 2011; 38: 1219-1236 DO
Page 21 and 22: Downloaded by [77.21.82.66] at 09:1
Page 31: Downloaded by [77.21.82.66] at 09:1
Page 39 and 40: http://jpet.aspetjournals.org/conte
Page 43 and 44: Electronic cigarettes (e-cigarettes
Page 59 and 60: http://www.ncbi.nlm.nih.gov/pubmed/
Page 71 and 72: http://onlinelibrary.wiley.com/doi/
Page 83 and 84:
Nachschlagewerk zum Thema E-Zigaret
Page 85 and 86:
http://www.ncbi.nlm.nih.gov/pubmed/
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
http://www.ncbi.nlm.nih.gov/pmc/art
Page 105 and 106:
http://www.ncbi.nlm.nih.gov/pmc/art
Page 107 and 108:
Page 109 and 110:
http://journal.nzma.org.nz/journal/
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
http://tobaccocontrol.bmj.com/conte
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
http://onlinelibrary.wiley.com/doi/
Page 129 and 130:
Page 131 and 132:
http://www.biomedcentral.com/1471-2
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
http://www.palgrave-journals.com/jp
Page 139 and 140:
http://www.palgrave-journals.com/jp
Page 141 and 142:
Novel Nicotine Delivery Systems and
Page 143 and 144:
market and permitted back only if a
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
http://www.bmj.com/content/343/bmj.
Page 157 and 158:
http://www.bmj.com/content/343/bmj.
Page 159 and 160:
WHO Technical Report Series 955 WHO
Page 161 and 162:
WHO Library Cataloguing-in-Publicat
Page 163 and 164:
iv 3.9 Recommendations 3.10 Acknowl
Page 165 and 166:
Dr A. Opperhuizen, Head of the Labo
Page 167 and 168:
1.1 Background 2 Regulation of toba
Page 169 and 170:
Lebanon as products that are import
Page 171 and 172:
manufacture or synthesized during e
Page 173 and 174:
delivers nicotine systemically via
Page 175 and 176:
Smokers trying to quit may use ENDS
Page 177 and 178:
12 4. Royal College of Physicians o
Page 179 and 180:
14 ANVISA RDC 41/09 Regulates as to
Page 181 and 182:
16 adolescent, of any smoking elect
Page 183 and 184:
18 Whether ENDS could be regarded a
Page 185 and 186:
20 Hürriyet Daily News, 17 January
Page 187 and 188:
3. Report on setting regulatory lim
Page 189 and 190:
N-nitrosonornicotine (NNN) 4-(methy
Page 191 and 192:
Table 1 Concentrations of tobacco-s
Page 193 and 194:
Table 3 Concentrations of tobacco-s
Page 195 and 196:
Per typical dose used: One advantag
Page 197 and 198:
different laboratories. In order to
Page 199 and 200:
hazardous than similar products, ha
Page 201 and 202:
3.11 References 1. The scientific b
Page 203 and 204:
4. Overall recommendations This rep
Page 205 and 206:
safety standards may be no less haz
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Clinical Medicine Insights: Case Re
Page 221 and 222:
25000 20000 15000 10000 5000 0 Jan
Page 223 and 224:
suggested that they may be effectiv
Page 225 and 226:
12. Imano H, Sato S, Kitamura A, et
Page 227 and 228:
Elektronische Zigarette auf dem Pr
Page 229 and 230:
Page 231 and 232:
http://www.medicalnewstoday.com/art
Page 233 and 234:
http://www.medicalnewstoday.com/art
Page 235 and 236:
Page 237 and 238:
988 • J. Neurosci., January 28, 2
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Introduzione La rapida espansione,
Page 251 and 252:
Nicotina Nicotine Glicoli - Gliceri
Page 253 and 254:
12 10 8 6 4 2 CO [mg/m3] 0 0m 7m 42
Page 255 and 256:
Naftalene / Naphthalene Parametro P
Page 257 and 258:
7 6 5 4 3 2 1 0 0.72 @ 11m 00s COT
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Schriften aus der Fakultät Humanwi
Page 267 and 268:
Nikotin: Molekulare und physiologis
Page 269 and 270:
Für meine Eltern, meinen Bruder, m
Page 271 and 272:
Inhaltsverzeichnis Inhaltsverzeichn
Page 273 and 274:
Inhaltsverzeichnis 5.4. Zusammenfas
Page 275 and 276:
Einleitung 1. Einleitung und Überb
Page 277 and 278:
Einleitung Im Rahmen des DFG-Schwer
Page 279:
Einleitung Integration der Resultat
Page 282 and 283:
18 Nikotinabhängigkeit - Geschicht
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 301 and 302:
Neurobiologie der Nikotinabhängigk
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
3.3.2. Kortikale Projektionsbahnen
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Therapie der Nikotinabhängigkeit 4
Page 341 and 342:
Therapie der Nikotinabhängigkeit t
Page 343 and 344:
Therapie der Nikotinabhängigkeit a
Page 345 and 346:
Therapie der Nikotinabhängigkeit R
Page 347 and 348:
Therapie der Nikotinabhängigkeit t
Page 349 and 350:
Therapie der Nikotinabhängigkeit o
Page 351:
Therapie der Nikotinabhängigkeit g
Page 354 and 355:
90 Voruntersuchungen im Bereich der
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
100 Die Untersuchung rimentalgruppe
Page 366 and 367:
102 Die Untersuchung 6.2. Untersuch
Page 368 and 369:
104 Die Untersuchung Abbildung 11:
Page 370 and 371:
106 Die Untersuchung geben. Außerd
Page 372 and 373:
108 Die Untersuchung Als rein trige
Page 374 and 375:
Page 376 and 377:
112 Die Untersuchung die notwendige
Page 378 and 379:
114 6.7. EEG-Untersuchung Die Unter
Page 380 and 381:
116 Die Untersuchung in pseudorando
Page 382 and 383:
118 Die Untersuchung Monitor eingeb
Page 384 and 385:
120 Die Untersuchung Die Lokalisati
Page 386 and 387:
122 Die Untersuchung 1991, 1994; Li
Page 388 and 389:
124 Die Untersuchung zentralen Able
Page 390 and 391:
126 Die Untersuchung Amplitude F-We
Page 392 and 393:
128 Die Untersuchung tude p1: T = -
Page 394 and 395:
130 Auswertung der Latenzzeiten Die
Page 396 and 397:
132 800 600 400 200 0 800 600 400 2
Page 398 and 399:
134 0,030 0,025 0,020 0,015 0,010 0
Page 400 and 401:
136 0,30 0,25 0,20 0,15 0,10 0,05 0
Page 402 and 403:
138 Die Untersuchung Die Ergebnisse
Page 404 and 405:
140 Die Untersuchung hinsichtlich i
Page 406 and 407:
142 Craving 35 30 25 20 15 10 CO2 t
Page 408 and 409:
144 Die Untersuchung Um ausschließ
Page 410 and 411:
146 Die Untersuchung erneut nicht f
Page 412 and 413:
148 6.8. fMRT-Untersuchung Die Unte
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
154 Die Untersuchung minimiert. Mit
Page 420 and 421:
156 Die Untersuchung Signifikanzsch
Page 422 and 423:
158 Die Untersuchung Anatomische Re
Page 424 and 425:
160 Die Untersuchung Aktivierungen
Page 426 and 427:
162 Die Untersuchung Anatomische Re
Page 428 and 429:
164 Die Untersuchung ten mit stärk
Page 430 and 431:
166 Die Untersuchung Die im Verglei
Page 432 and 433:
168 Die Untersuchung sierungsprozes
Page 434 and 435:
170 Die Untersuchung 4,215, df = 5,
Page 436 and 437:
172 Die Untersuchung Einklang steht
Page 439 and 440:
Integration und Diskussion der Date
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
8. Ausblick Ausblick Die vorliegend
Page 455:
Ausblick Man könnte sagen, daß da
Page 458 and 459:
194 Literaturverzeichnis Albrecht,
Page 460 and 461:
196 Literaturverzeichnis Balfour, D
Page 462 and 463:
198 Literaturverzeichnis Benwell, M
Page 464 and 465:
200 Literaturverzeichnis Brody, A.
Page 466 and 467:
202 Literaturverzeichnis Chu, B. &
Page 468 and 469:
204 Literaturverzeichnis Domino, E.
Page 470 and 471:
206 Literaturverzeichnis Eviatar, Z
Page 472 and 473:
208 Literaturverzeichnis Grove, G.,
Page 474 and 475:
210 Literaturverzeichnis Hirzel, G.
Page 476 and 477:
212 Literaturverzeichnis Ianilli, E
Page 478 and 479:
214 Literaturverzeichnis Kirch, D.
Page 480 and 481:
216 Literaturverzeichnis Leonhard,
Page 482 and 483:
218 Literaturverzeichnis Maskos, U.
Page 484 and 485:
220 Literaturverzeichnis Naqvi, N.
Page 486 and 487:
222 Literaturverzeichnis Perkins, K
Page 488 and 489:
224 Literaturverzeichnis Rehms, W.,
Page 490 and 491:
226 Literaturverzeichnis Roth, G. (
Page 492 and 493:
228 Literaturverzeichnis Schultz, W
Page 494 and 495:
230 Literaturverzeichnis Stein, E.
Page 496 and 497:
232 Literaturverzeichnis Thuerauf,
Page 498 and 499:
234 Literaturverzeichnis Warburton,
Page 500 and 501:
236 Literaturverzeichnis World Heal
Page 503 and 504:
Verzeichnis der Abbildungen Verzeic
Page 505:
Verzeichnis der Tabellen Verzeichni
Page 508 and 509:
244 Anhang C3 C4 Fz Pz Cz P1 0,0189
Page 510 and 511:
Page 512 and 513:
Page 514 and 515:
Page 516 and 517:
http://www.nature.com/npp/journal/v
Page 518 and 519:
Page 520 and 521:
Page 522 and 523:
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536:
Page 539 and 540:
http://pharmrev.aspetjournals.org/c
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
Page 547 and 548:
http://www.jahonline.org/article/S1
Page 549 and 550:
Page 551 and 552:
Page 553 and 554:
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
Research paper Figure 1 ‘eGo’ m
Page 561 and 562:
4 Cheah NP, et al. Tob Control 2012
Page 563 and 564:
Research paper Figure 3 ‘Tattoo
Page 565 and 566:
Downloaded from tobaccocontrol.bmj.
Page 567 and 568:
Original article Adolescent Males
Page 569 and 570:
146 (smoked less than 100 cigarette
Page 571 and 572:
148 Table 3 Correlates of willingne
Page 573 and 574:
150 [12] Bell K, Keane H. Nicotine
Page 575 and 576:
Gutachten Nr. 12-09556-4/gch Diese
Page 577 and 578:
Untersuchungsergebnisse: Probe 1 2
Page 579 and 580:
Int. J. Environ. Res. Public Health
Page 581 and 582:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
208 Adkison et al / Am J Prev Med 2
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
Page 607 and 608:
Page 609 and 610:
What is it? Liquid contents •Glyc
Page 611 and 612:
Design Smokers N=20 e-cigarette use
Page 613 and 614:
Page 615 and 616:
• • •
Page 617 and 618:
© 1,3-bis(3-phenoxyphenoxy)
Page 619 and 620:
©
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
Barbeau et al. Addiction Science &
Page 627 and 628:
Table 1 Identified themes and examp
Page 629 and 630:
Barbeau et al. Addiction Science &
show all

studiensammlung

Create successful ePaper yourself

Delete template?

Save as template?